<DOC>
	<DOCNO>NCT02583009</DOCNO>
	<brief_summary>This clinical study determine optimum dose PAC-14028 cream therapeutic confirmatory clinical study evaluate safety therapeutic equivalence PAC-14028 cream 0.1 % , 0.3 % 1.0 % patient rosacea .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy PAC-14028 Cream Rosacea</brief_title>
	<detailed_description />
	<mesh_term>Rosacea</mesh_term>
	<criteria>Male female patient age 19 70 year old Among patient diagnose erythematotelangiectatic papulopustular rosacea accordance diagnostic criterion National Rosacea Society Expert Committee Subjects rosacea score 2 accord Investigator Global Assessment ( IGA ) screen Those ca n't diagnose assessed rosacea due presence trauma , tattoo , scar , excessive hair facial region Those receive facial laser treatment within 6 week Those administered oral retinoid therapeutic vitamin A within 6 month Those received hormonal treatment estrogen within 3 month Those administer systemic antibiotic systemic steroid formulation within 4 week Those administered local retinoid , local steroid local antibiotic local medication treatment rosacea face within 4 week Those history blood disorder serious effect clinical study Women pregnant , lactate plan pregnant clinical study period woman childbearing potential use available contraceptive method</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>